CHRONIC MYELOID LEUKEMIA TREATMENT MARKET ANALYSIS

Chronic Myeloid Leukemia Treatment Market, By Drug Type (Tyrosine Kinase Inhibitors, Antimetabolites, and Others), By Route of Administration (Oral, Parenteral, Topical, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa)

On September 18, 2024, Chronic Malignancies Working Party (CMWP), a specialized group within the European Society for Blood and Marrow Transplantation (EBMT) focused on improving outcomes for patients with chronic hematologic malignancies, announced that it had joined the chronic myeloid leukemia (CML) global community to commemorate the World CML Awareness Day
On March 14, 2024, Novartis AG, a biopharmaceutical company, announced the introduction of Asciminib, a pioneering treatment for CML that specifically targets the ABL myristoyl pocket (STAMP)
In February 2023, Xspray Pharma AB, a pharmaceutical company, announced an agreement with EVERSANA, an independent provider of global services to the life sciences industry, to support the U.S. launch and commercialization of the company's first innovative cancer therapy Dasynoc for the treatment of CML and acute lymphatic leukemia (ALL)